ERBB2 and breast cancer: In light of favorable disease-related outcomes seen in contemporary trials for HER2-positive early breast cancer, ongoing efforts increasingly emphasize treatment de-escalation as a means of optimizing health-related quality of life (HRQOL) while sustaining treatment efficacy.